gefitinib has been researched along with s 1743 in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (s 1743) | Trials (s 1743) | Recent Studies (post-2010) (s 1743) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 1,228 | 569 | 704 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aerts, JGJV; Dingemans, AC; Hurkmans, DP; Mathijssen, RHJ; Oomen-de Hoop, E; Paats, MS; van der Leest, CH; van Leeuwen, RW; van Thiel, ERE; Veerman, GDM | 1 |
1 trial(s) available for gefitinib and s 1743
| Article | Year |
|---|---|
Influence of esomeprazole on the bioavailability of afatinib: A pharmacokinetic cross-over study in patients with non-small cell lung cancer.
Topics: Afatinib; Biological Availability; Carcinoma, Non-Small-Cell Lung; Cross-Over Studies; ErbB Receptors; Erlotinib Hydrochloride; Esomeprazole; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proton Pump Inhibitors | 2022 |